Clinical Trials
ASD Study (Soroka)
Evaluating the safety, tolerability and efficacy of SCI-210 in children with autism spectrum disorder.
Objective
Randomized
Study
evaluate the safety, tolerability and efficacy of SCI-210 in children with ASD in a randomized, double-blind, placebo-controlled crossover study.
Recruitment
27
Patients recruited
As of December 2025, 27 patients were recruited.
Trial site
01
Trial site
Clinical Research Center and Negev Autism Center, Soroka University Medical Center, Be’er Sheva, Israel.
Time
20 + 20
Weeks
20-week randomized, double-blind, placebo-controlled crossover trial of 60 children. 30 participants receive SCI-210 or SCI-210 placebo (CBD active, CannAmide™ placebo) for 20 weeks, followed by a 2-week washout and crossover for an additional 20 weeks.
Regulatory pathway
Phase III*
route
Designated Phase III* via the medical cannabis route.